Every 8-K that HEALTHLYNKED CORP (HLYK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HLYK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HLYK filings page.
HealthLynked Corp. appointed director George O’Leary, 63, as part-time Interim Chief Financial Officer effective July 13, 2026, under a consulting engagement for three days per week at $15,000 per month. He also received 35,000 stock options with a $3.50 exercise price that vest only if the company receives approval for listing on the Nasdaq Capital Market while he is serving as interim CFO or during a 30-day notice period after termination.
On the same date, Jeremy Daniel ceased serving as Chief Financial Officer and moved into a corporate accounting role, with the company stating the transition did not result from any disagreement with management, the board, or its committees. Effective July 24, 2026, HealthLynked will eliminate the Chief Operating Officer position; incumbent COO Duncan McGillivray will leave that role and continue on an as-needed basis under an Independent Consulting Agreement as Senior Strategic Advisor.
HealthLynked Corp. entered into a related-party financing by issuing a senior secured convertible promissory note with principal of $5,715,811.98 to the Mary S. Dent Gifting Trust, which is controlled by its CEO and Chairman, Dr. Michael Dent.
The new note consolidates prior obligations, including earlier promissory notes with principal of $4,338,191.70 and accrued interest of $737,180.26, undocumented advances of $339,840.02, and $300,600.00 of unpaid 2017 compensation. It carries 12% annual interest, rising to 18% upon uncured default, matures on February 2, 2029, and is secured by a first-priority lien on all company assets. The note is optionally convertible into common stock at $4.25 per share and was issued in a private, unregistered transaction relying on Section 4(a)(2) and Regulation D exemptions.
HealthLynked Corp. reported several leadership changes. The company appointed Duncan McGillivray as Chief Operating Officer effective December 8, 2025. He has more than 30 years of experience in healthcare, capital markets, and large-scale project finance, including work on a targeted $40M construction project in Miami and helping close over $200 million of funded projects for community health facilities.
His initial base salary is $120,000 per year, increasing to $150,000 if the company successfully uplists to the Nasdaq Capital Market, and he will receive up to 180,000 restricted stock units, split between time-based and uplisting-based vesting. Effective December 1, 2025, HealthLynked also expanded its Board from six to eight members and appointed Jason Bishara and Chris G. Pulos as non‑employee directors, each receiving annual compensation of $20,000 in common stock vesting quarterly over one year.